Sensitivity analysis.

<p>^aNumbers rounded to nearest CAN$1.</p>b<p>Each incremental value compares the value of that strategy to next most costly, nondominated, strategy.</p>c<p>Dominated is defined as more costly and fewer QALYs compared with a comparator strategy.</p

Multivariate predictors of inadequate bowel preparation.

<p>Multivariate predictors of inadequate bowel preparation.</p

Study population characteristics.

<p>Study population characteristics.</p

Probabilistic sensitivity analysis.

<p>An incremental cost-effectiveness scatterplot comparing FIT-mid with no screening in which the uncertainty in all model inputs has been tested simultaneously. Data points in the lower right quadrant reflect situations where FIT-mid is more effective and less costly than no screening.</p

Base case test performance characteristics for the screening modalities.

<p>Base case test performance characteristics for the screening modalities.</p

Cancer outcomes and number of screening tests required during the lifetimes for a hypothetical 100,000 average risk patient cohort.

a<p><i>n</i> cancers overall include symptomatic and screen found CRC.</p

Bowel preparation quality.

<p>Bowel preparation quality.</p

Base case direct health care costs and nonmedical costs and ranges considered.

a<p>FOBT: includes cost of FOBT kit (CAN$5), processing (CAN$7).</p>b<p>Diagnostic colonoscopy: includes physician cost of diagnostic colonoscopy (CAN$327), and nonphysician cost of colonoscopy (CAN$530).</p>c<p>Therapeutic colonoscopy: includes physician cost of therapeutic colonoscopy (CAN$401), and nonphysician cost of therapeutic colonoscopy (CAN$598).</p>d<p>Includes patient ± caregiver time and travel costs, but excludes productivity losses <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1000370#pmed.1000370-Guidelines1" target="_blank">[29]</a>.</p

Base case model inputs and ranges considered.

a<p>Minor adjustments were applied to the rates used in the US Multi-Society Task Force model <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1000370#pmed.1000370-Winawer2" target="_blank">[32]</a> such that the total of our baseline prevalence of CRC plus the number of new CRCs developing in our natural history arm closely approximated the number of CRCs observed in the control arms of the FOBT RCTs <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1000370#pmed.1000370-Hardcastle1" target="_blank">[9]</a>–<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1000370#pmed.1000370-Mandel1" target="_blank">[11]</a>.</p

Model bubble diagram.

<p>This diagram depicts the general health states and flow through the model.</p